To evaluate the effectiveness of PriMatrix in the treatment of DFUs in subjects without significantly compromised arterial circulation.

Inclusion Criteria:

• Type I or Type II diabetes with investigator-confirmed reasonable metabolic control
• Peripheral neuropathy
• A full thickness diabetic plantar foot ulcer of at least 1 cm2 but not exceeding 10 cm2 in area
• An ulcer which has been in existence for a minimum of 30 days, prior to the day of screening

Exclusion Criteria:

• Suspected or confirmed signs/symptoms of wound infection
• Wounds with exposed bone or tendon
• Hypersensitivity to bovine collagen

Patients with a diabetic foot ulcer and meet the inclusion/exclusion criteria